USANA Health Sciences Announces Record First Quarter Financial Results
- Net sales increased by 9.7% to $169.1 million
- Net earnings increased by 29.3%, while earnings per share increased by 42.2% to $1.28
- Company raises 2013 financial outlook
SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE: USNA) today announced record financial results for its fiscal first quarter ended March 30, 2013.
Financial Performance
Net sales for the first quarter of 2013 increased by 9.7% to $169.1 million, compared with $154.1 million in the prior-year period. This growth in net sales was driven by increases in both the Company’s Asia Pacific and North America/Europe regions. Favorable changes in currency exchange rates also contributed approximately $900,000 to the top line for the quarter.
Net earnings for the first quarter increased to $17.8 million, an improvement of 29.3%, compared with the prior-year period. This increase was due primarily to higher net sales and lower relative Associate incentive expense for the quarter. The relative decrease in Associate incentives expense was attributable to the change to the lifetime matching bonus program, which is now fully implemented. Earnings per share for the quarter increased by 42.2% to $1.28, compared with $0.90 in the first quarter of the prior year. This improvement in earnings per share was attributable to higher net earnings and a lower number of diluted shares outstanding, which resulted from the Company’s share repurchases over the last 12 months. Total diluted common shares outstanding as of March 30, 2013 were 13.9 million, compared with 15.3 million as of March 31, 2012.
The Company’s Chief Executive Officer, Dave Wentz, said, “For the first quarter of 2013 USANA again delivered record results in sales and earnings per share. During the quarter, our management team continued to execute our strategic initiatives, which are focused on generating worldwide customer growth, growing our Greater China region, advancing our personalization initiatives, and driving new market expansion.”
Regional Results
Net sales in Asia Pacific increased by 9.9% to $104.9 million, compared with $95.5 million for the first quarter of the prior year. This improvement was due to strong sales growth in our Greater China and Southeast Asia Pacific regions, which was driven by a 6.3% increase in the number of active Associates in Asia Pacific.
“We continue to see solid growth in Asia Pacific, with double-digit local currency growth in several of our markets in that region,” continued Mr. Wentz. “We remain focused on growing our Greater China region, and are pleased to have received during the quarter government approval in mainland China to expand our direct selling activities in three additional provinces. We continue to be optimistic about our growth opportunity in this region, as we expand our customer base and the reach of our world-class products.”
During the first quarter of 2013, net sales in North America/Europe increased by 9.4% to $64.2 million, compared with $58.6 million in the prior-year period. The number of Active Associates in North America/Europe increased 1.3% and the number of Preferred Customers increased 3.8% during the first quarter, compared with the first quarter of 2012.
Mr. Wentz added, “We continue to see improvement in our operating trends in North America, particularly in our top-line results. During the quarter, we saw double-digit sales growth in the U.S. and Mexico, as well as strong Associate growth in Mexico. Our focus continues to be on increasing active Associate counts in the U.S. and Canada, and we have several initiatives planned during 2013 to accomplish this objective. We are also excited to announce the addition of Colombia to this region, which we expect to open in the third quarter of 2013. We believe Colombia will be a successful market for USANA and an excellent entry point into South America.”
The Company maintained its successful track record of generating meaningful levels of cash from operations and ended the quarter with $71 million in cash and cash equivalents. For the first quarter, cash generated from operations totaled $20.3 million. During the quarter, the Company invested $18.1 million to repurchase 414,000 shares of the Company’s common stock.
Outlook
The Company reiterated consolidated net sales outlook and provided the following updated earnings per share outlook for 2013:
- Consolidated net sales between $700 million and $720 million
- Earnings per share between $5.25 and $5.40, versus the previous outlook of between $5.10 and $5.25
Chief Financial Officer, Paul Jones, commented, “Our first quarter financial results are a strong start to what we expect will be another record year for USANA. As we work to accomplish each of our strategic initiatives in 2013, we will continue to invest in our personalization and customer growth strategies, which will include offering region-specific incentives to our Associate sales force. As demonstrated by our increased earnings per share outlook for 2013, we continue to anticipate growth in sales and earnings during the current year.”
Conference Call
USANA will hold a conference call and webcast to discuss this announcement with investors on Wednesday, April 24, 2013 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://www.usanahealthsciences.com.
About USANA
USANA develops and manufactures high-quality nutritional, personal care, and weight-management products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France and Belgium. More information on USANA can be found at http://www.usanahealthsciences.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.
| USANA Health Sciences, Inc. | ||||||||||
| Consolidated Statements of Earnings | ||||||||||
| (In thousands, except per share data) | ||||||||||
| (Unaudited) | ||||||||||
| Quarter Ended | ||||||||||
| 31-Mar-12 | 30-Mar-13 | |||||||||
| Net sales | $ | 154,120 | $ | 169,082 | ||||||
| Cost of sales | 27,217 | 30,261 | ||||||||
| Gross profit | 126,903 | 138,821 | ||||||||
| Operating expenses | ||||||||||
| Associate incentives | 68,009 | 69,855 | ||||||||
| Selling, general and administrative | 38,032 | 42,404 | ||||||||
| Earnings from operations | 20,862 | 26,562 | ||||||||
| Other income (expense) | 132 | (26 | ) | |||||||
| Earnings before income taxes | 20,994 | 26,536 | ||||||||
| Income taxes | 7,243 | 8,757 | ||||||||
| NET EARNINGS | $ | 13,751 | $ | 17,779 | ||||||
| Earnings per share - diluted | $ | 0.90 | $ | 1.28 | ||||||
| Weighted average shares outstanding - diluted | 15,288 | 13,903 | ||||||||
| USANA Health Sciences, Inc. | |||||||||
| Consolidated Balance Sheets | |||||||||
| (In thousands) | |||||||||
| (Unaudited) | |||||||||
| As of | As of | ||||||||
| 29-Dec-12 | 30-Mar-13 | ||||||||
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash and cash equivalents | $ | 70,839 | $ | 71,047 | |||||
| Inventories | 36,481 | 42,974 | |||||||
| Other current assets | 25,225 | 19,633 | |||||||
| Total current assets | 132,545 | 133,654 | |||||||
| Property and equipment, net | 61,751 | 60,715 | |||||||
| Goodwill | 17,890 | 17,933 | |||||||
| Intangible assets, net | 42,085 | 41,963 | |||||||
| Deferred income taxes | 5,956 | 6,149 | |||||||
| Other assets | 7,128 | 8,243 | |||||||
| Total assets | $ | 267,355 | $ | 268,657 | |||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
| Current Liabilities | |||||||||
| Accounts payable | $ | 7,040 | $ | 8,152 | |||||
| Other current liabilities | 63,804 | 61,894 | |||||||
| Total current liabilities | 70,844 | 70,046 | |||||||
| Other long-term liabilities | 938 | 909 | |||||||
| Deferred income taxes | 10,001 | 10,054 | |||||||
| Stockholders' equity | 185,572 | 187,648 | |||||||
| Total liabilities and stockholders' equity | $ | 267,355 | $ | 268,657 | |||||
| USANA Health Sciences, Inc. | ||||||||||||||||||
| Sales by Region | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| (In thousands) | ||||||||||||||||||
| Quarter Ended | ||||||||||||||||||
| 31-Mar-12 | 30-Mar-13 | |||||||||||||||||
|
Region |
||||||||||||||||||
| North America / Europe | $ | 58,632 | 38.1 | % | $ | 64,152 | 37.9 | % | ||||||||||
| Asia Pacific | ||||||||||||||||||
| Southeast Asia Pacific | 32,252 | 20.9 | % | 35,309 | 20.9 | % | ||||||||||||
| Greater China | 56,635 | 36.7 | % | 62,985 | 37.3 | % | ||||||||||||
| North Asia | 6,601 | 4.3 | % | 6,636 | 3.9 | % | ||||||||||||
| Asia Pacific Total | 95,488 | 61.9 | % | 104,930 | 62.1 | % | ||||||||||||
| Total | $ | 154,120 | 100.0 | % | $ | 169,082 | 100.0 | % | ||||||||||
| Active Associates by Region (1) | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| As of | ||||||||||||||||||
| 31-Mar-12 | 30-Mar-13 | |||||||||||||||||
|
Region |
||||||||||||||||||
| North America / Europe | 77,000 | 35.1 | % | 78,000 | 34.1 | % | ||||||||||||
| Asia Pacific | ||||||||||||||||||
| Southeast Asia Pacific | 51,000 | 23.3 | % | 56,000 | 24.4 | % | ||||||||||||
| Greater China | 83,000 | 37.9 | % | 87,000 | 38.0 | % | ||||||||||||
| North Asia | 8,000 | 3.7 | % | 8,000 | 3.5 | % | ||||||||||||
| Asia Pacific Total | 142,000 | 64.9 | % | 151,000 | 65.9 | % | ||||||||||||
| Total | 219,000 | 100.0 | % | 229,000 | 100.0 | % | ||||||||||||
| (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased product at any time during the most recent three-month period, either for personal use or for resale. | ||||||||||||||||||
| Active Preferred Customers by Region (2) | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| As of | ||||||||||||||||||
| 31-Mar-12 | 30-Mar-13 | |||||||||||||||||
|
Region |
||||||||||||||||||
| North America / Europe | 53,000 | 79.1 | % | 55,000 | 82.1 | % | ||||||||||||
| Asia Pacific | ||||||||||||||||||
| Southeast Asia Pacific | 6,000 | 9.0 | % | 7,000 | 10.4 | % | ||||||||||||
| Greater China | 7,000 | 10.4 | % | 3,000 | 4.5 | % | ||||||||||||
| North Asia | 1,000 | 1.5 | % | 2,000 | 3.0 | % | ||||||||||||
| Asia Pacific Total | 14,000 | 20.9 | % | 12,000 | 17.9 | % | ||||||||||||
| Total | 67,000 | 100.0 | % | 67,000 | 100.0 | % | ||||||||||||
| (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased product at any time during the most recent three-month period. | ||||||||||||||||||
USANA Health Sciences, Inc.
Investors contact:
Patrique
Richards, 801-954-7961
Investor Relations
investor.relations@us.usana.com
Media
contact:
Dan Macuga, 801-954-7280
Public Relations
Source: USANA Health Sciences, Inc.
Released April 23, 2013